Replies to post #160426 on Cytodyn Inc (CYDY)

[Cynmark24]

Wishful thinking, daemon, as there is always something "brewing" to keep us from dumping our shares. Then the "brew" is finished and as always, there is nothing there, just a bunch of "maybe's," "expecting to," "planning to," and "hoping to," all code words for "there's nothing going on."

I'm just as committed to the success of the company as you are, but apparently have "separation anxiety."

[Monroe1]

Good eye daemon57. As the word of leronlimab spreads globally, any country could be in the running to make a deal with CytoDyn. Some likely candidates IMO are those with a bit more independence from our FDA/CDC like Philippines, Malaysia, India, and especially Brazile. Brazil looks most favorable due to their terrible Covid problem and variants and huge dense population centers. Remember the recent deal last month with BioMM SA? Read closely. Would it be Brazilian ANVISA is ready to initiate EUA conditional or otherwise? Their SOC with our FDA expired in 2017. Regardless, it has non-binding intent ie not obligated, so Leronlimab could be good to go.

"CytoDyn has committed to conduct clinical trials in Brazil for all current indications for leronlimab (i.e., Long-Hauler COVID-19, NASH and cancer).[Room for a partnership deal in any indication?]

Heraldo Marchezini, Chief Executive Officer of Biomm S.A., commented, “We are very pleased with our recently executed exclusive supply and distribution agreement with CytoDyn. Our urgent goal is to provide leronlimab to Brazilians critically ill with COVID-19.”

Biomm's mission is to develop, produce and market global competitive biomedicines with quality and accessibility. The company's focus is developing biological products, aiming to guarantee national self-sufficiency. Due to its innovator DNA, the company is pioneer in biotechnological drugs in Brazil. Founded in 2002, Biomm’s headquarters and factory are in Nova Lima (MG), with capacity to produce 20 million of insulin per year, based on advanced and innovative technologies that guarantee the medicines quality. Looks ripe for a deal to me. CYDY$ Good job Nader.